These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 16272569
1. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy. Nakayama D, Misumi S, Mukai R, Tachibana K, Umeda M, Shibata H, Takamune N, Shoji S. J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569 [Abstract] [Full Text] [Related]
2. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4. Misumi S, Takamune N, Ido Y, Hayashi S, Endo M, Mukai R, Tachibana K, Umeda M, Shoji S. Biochem Biophys Res Commun; 2001 Aug 03; 285(5):1309-16. PubMed ID: 11478800 [Abstract] [Full Text] [Related]
3. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine. Misumi S, Nakajima R, Takamune N, Shoji S. J Virol; 2001 Dec 03; 75(23):11614-20. PubMed ID: 11689643 [Abstract] [Full Text] [Related]
4. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. Misumi S, Endo M, Mukai R, Tachibana K, Umeda M, Honda T, Takamune N, Shoji S. J Biol Chem; 2003 Aug 22; 278(34):32335-43. PubMed ID: 12771150 [Abstract] [Full Text] [Related]
5. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Zuber B, Hinkula J, Vödrös D, Lundholm P, Nilsson C, Mörner A, Levi M, Benthin R, Wahren B. Virology; 2000 Dec 20; 278(2):400-11. PubMed ID: 11118363 [Abstract] [Full Text] [Related]
6. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW. J Infect Dis; 2005 Mar 15; 191(6):890-8. PubMed ID: 15717264 [Abstract] [Full Text] [Related]
7. Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge. Misumi S, Nakayama D, Kusaba M, Iiboshi T, Mukai R, Tachibana K, Nakasone T, Umeda M, Shibata H, Endo M, Takamune N, Shoji S. J Immunol; 2006 Jan 01; 176(1):463-71. PubMed ID: 16365439 [Abstract] [Full Text] [Related]
8. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, Springer MS, Moore JP. Virology; 2004 Oct 10; 328(1):19-29. PubMed ID: 15380354 [Abstract] [Full Text] [Related]
9. Alterations in mast cell function and survival following in vitro infection with human immunodeficiency viruses-1 through CXCR4. Taub DD, Mikovits JA, Nilsson G, Schaffer EM, Key ML, Petrow-Sadowski C, Ruscetti FW. Cell Immunol; 2004 Aug 10; 230(2):65-80. PubMed ID: 15598422 [Abstract] [Full Text] [Related]
10. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H. J Virol; 2007 Jan 10; 81(2):525-31. PubMed ID: 17079299 [Abstract] [Full Text] [Related]
11. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. Khurana S, Kennedy M, King LR, Golding H. J Virol; 2005 Jun 10; 79(11):6791-800. PubMed ID: 15890918 [Abstract] [Full Text] [Related]
12. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P. AIDS; 2007 Jun 19; 21(10):1263-72. PubMed ID: 17545702 [Abstract] [Full Text] [Related]
13. R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Saïdi H, Magri G, Nasreddine N, Réquena M, Bélec L. Virology; 2007 Feb 05; 358(1):55-68. PubMed ID: 16934308 [Abstract] [Full Text] [Related]
14. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, Olde B, Owman C, Fenyö EM. AIDS; 2003 Dec 05; 17(18):2561-9. PubMed ID: 14685050 [Abstract] [Full Text] [Related]
15. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. Clin Infect Dis; 2007 Feb 15; 44(4):591-5. PubMed ID: 17243065 [Abstract] [Full Text] [Related]
16. Genotypic coreceptor analysis. Sierra S, Kaiser R, Thielen A, Lengauer T. Eur J Med Res; 2007 Oct 15; 12(9):453-62. PubMed ID: 17933727 [Abstract] [Full Text] [Related]
17. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. Clin Infect Dis; 2008 May 15; 46(10):1617-23. PubMed ID: 18419499 [Abstract] [Full Text] [Related]
18. Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. Casper CH, Clevestig P, Carlenor E, Leitner T, Anzén B, Lidman K, Belfrage E, Albert J, Bohlin AB, Navér L, Lindgren S, Fenyö EM, Ehrnst AC. J Infect Dis; 2002 Oct 01; 186(7):914-21. PubMed ID: 12232831 [Abstract] [Full Text] [Related]
19. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, Clapham PR. Antiviral Res; 2005 Nov 01; 68(2):96-108. PubMed ID: 16157392 [Abstract] [Full Text] [Related]
20. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors. Pontow S, Ratner L. J Virol; 2001 Dec 01; 75(23):11503-14. PubMed ID: 11689632 [Abstract] [Full Text] [Related] Page: [Next] [New Search]